Universitätsklinikum Gießen und Marburg (UKGM)

Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry—comparison of three different GPA prognostic scores (2021) Riecke K, Müller V, Weide R, Schmidt M, Park‐simon TW, Möbus V, Mundhenke C, et al. Journal article Hormonal Contraception. Guideline of the DGGG, OEGGG and SGGG (S3 Level, AWMF Registry Number 015/015, January 2020) (2021) Franik S, Bauersachs R, Beyer-Westendorf J, Buchholz T, Bühling K, Diener HC, Erath A, et al. Journal article Atopic skin diathesis rather than atopic dermatitis is associated with specific contact allergies (2021) Forkel S, Cevik N, Schill T, Worm M, Mahler V, Weisshaar E, Vieluf D, et al. Journal article Atopische Hautdiathese ist stärker mit spezifischen Kontaktallergien assoziiert als atopische Dermatitis (2021) Forkel S, Cevik N, Schill T, Worm M, Mahler V, Weisshaar E, Vieluf D, et al. Journal article Biaxial flexural strength of zirconia: A round robin test with 12 laboratories (2021) Spintzyk S, Geis-Gerstorfer J, Bourauel C, Keilig L, Lohbauer U, Brune A, Greuling A, et al. Journal article Appendicitis during the COVID-19 lockdown: results of a multicenter analysis in Germany. (2021) Willms AG, Oldhafer KJ, Conze S, Thasler WE, Von Schassen C, Hauer T, Huber T, et al. Journal article Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (2021) Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, et al. Journal article Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology (2021) Skrahina V, Grittner U, Beetz C, Skripuletz T, Juenemann M, Kraemer HH, Hahn K, et al. Journal article Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA (2021) Marme F, Hanusch C, Furlanetto J, Denkert C, Link T, Untch M, Blohmer JU, et al. Conference contribution A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE) (2021) Loibl S, Schmidt M, Luebbe K, Decker T, Thill M, Bauer L, Mueller V, et al. Conference contribution